Recent Advances in Micro-Electro-Mechanical Devices for Controlled Drug Release Applications

In recent years, controlled release of drugs has posed numerous challenges with the aim of optimizing parameters such as the release of the suitable quantity of drugs in the right site at the right time with the least invasiveness and the greatest possible automation. Some of the factors that challenge conventional drug release include long-term treatments, narrow therapeutic windows, complex dosing schedules, combined therapies, individual dosing regimens, and labile active substance administration. In this sense, the emergence of micro-devices that combine mechanical and electrical components, so called micro-electro-mechanical systems (MEMS) can offer solutions to these drawbacks. These devices can be fabricated using biocompatible materials, with great uniformity and reproducibility, similar to integrated circuits. They can be aseptically manufactured and hermetically sealed, while having mobile components that enable physical or analytical functions together with electrical components. In this review we present recent advances in the generation of MEMS drug delivery devices, in which various micro and nanometric structures such as contacts, connections, channels, reservoirs, pumps, valves, needles, and/or membranes can be included in their design and manufacture. Implantable single and multiple reservoir-based and transdermal-based MEMS devices are discussed in terms of fundamental mechanisms, fabrication, performance, and drug release applications.

Electrochemical Behavior and Redox-Dependent Disassembly of Gallic Acid/FeIII Metal-Phenolic Networks

Metal-phenolic networks (MPNs) are a versatile class of organic-inorganic hybrid systems that are generating interest for applications in catalysis, bioimaging, and drug delivery. These self-assembled MPNs possess metal-coordinated structures and may potentially serve as redox-responsive platforms for triggered disassembly or drug release. Therefore, a comprehensive study of the reduction and oxidation behavior of MPNs for evaluating their redox responsiveness, specific conditions required for their disassembly, and the kinetics of metal ion release, is necessary. Using a representative MPN gallic acid-iron (GA/Fe^III) system, we conducted electrochemical studies to provide fundamental insights into the redox behavior of these MPNs. We demonstrate that GA/Fe^III is redox active, and evaluate its electrochemical reversibility, identify the oxidation state of the redox-active species, and provide information regarding the stability of the networks toward reductive stimuli and specific redox conditions required for the "on-off" or continuous release of Fe^III. Overall, through studying the redox properties of GA/Fe^III films, we advance the understanding of multifunctional iron-containing MPN platforms that may have practical significance for biologically relevant applications.

Plasmonic nanocarrier grid-enhanced Raman sensor for studies of anticancer drug delivery

Targeted drug delivery systems using nanoparticle nanocarriers offer remarkable promise for cancer therapy by discriminating against devastating cytotoxicity of chemotherapeutic drugs to healthy cells. To aid in the development of new drug nanocarriers, we propose a novel plasmonic nanocarrier grid-enhanced Raman sensor which can be applied for studies and testing of drug loading onto the nanocarriers, attachment of targeting ligands, dynamics of drug release, assessment of nanocarrier stability in biological environment, and general capabilities of the nanocarrier. The plasmonic nanogrid sensor offers strong Raman enhancement due to the overlapping plasmonic fields emanating from the nearest-neighbor gold nanoparticle nanocarriers and creating the enhancement "hot spots". The sensor has been tested for immobilization of an anticancer drug gemcitabine (2',2'-difluoro-2'-deoxycytidine, GEM) which is used in treatment of pancreatic tumors. The drawbacks of currently applied treatment include high systemic toxicity, rapid drug decay, and low efficacy (ca. 20%). Therefore, the development of a targeted GEM delivery system is highly desired. We have demonstrated that the proposed nanocarrier SERS sensor can be utilized to investigate attachment of targeting ligands to nanocarriers (attachment of folic acid ligand recognized by folate receptors of cancer cells is described). Further testing of the nanocarrier SERS sensor involved drug release induced by lowering pH and increasing GSH levels, both occurring in cancer cells. The proposed sensor can be utilized for a variety of drugs and targeting ligands, including those which are Raman inactive, since the linkers can act as the Raman markers, as illustrated with mercaptobenzoic acid and para-aminothiophenol.